Guiding psychiatric treatment using inflammatory biomarkers such as IL-6, and IL-8 may lead to selection of better drugs to treat each patient’s specific pathophysiological disruptions that contribute to their depression or anxiety. The gene discussed is CXCL8; the disease is major depressive disorder.